CA-GUIDEWIRE-SOFTWARE
12.3.2020 10:02:10 CET | Business Wire | Press release
Shift Technology , a provider of AI‑native fraud detection and claims automation solutions for the global insurance industry, and Guidewire Software, Inc. (NYSE: GWRE), provider of the industry platform general insurers rely upon, today announced that Shift’s Force add-on , created using the Guidewire DevConnect developer environment, is now available in the Guidewire Marketplace . Shift’s Ready for Guidewire add-on provides Guidewire customers on ClaimCenter with a seamless integration between Shift’s Force fraud detection solution and ClaimCenter, enabling the efficient transfer of claims data between the two solutions and facilitating real-time fraud detection.
The total cost of insurance fraud in Europe is estimated to be 13 billion euros per year according to Insurance Europe . To address the growing and complex issue of insurance fraud and control premiums for policyholders, Shift’s Ready for Guidewire Force add-on, integrated with Guidewire ClaimCenter, automatically triggers fraud alerts in the ClaimCenter electronic claim file and directs the workflow into the appropriate automated or human-based process best suited for the type and level of suspected fraud.
Shift offers insurers technology solutions that use artificial intelligence and advanced data science to identify claims that may be fraudulent. Using a combination of insurers’ internal data, and external, third-party data, the company’s Force solution makes correlations between these multiple sources to identify suspicious behavior that may indicate that a claim is not legitimate.
“The ability to share data and information between ClaimCenter and Force, in real time, offers tremendous benefits to our joint customers,” stated Jeremy Jawish, CEO and co‑founder, Shift Technology. “By knowing if a claim is suspicious or not, and just how suspicious it is, claims professionals will be better empowered to make business-critical decisions. For example, should they apply ‘straight through processing’ and pay the claim at the time of FNOL or carry out standard processing by the claims handling team? Perhaps they should bring in an expert to verify particular details or refer the claim to the fraud investigation team. Our partnership helps give claims professionals the knowledge to make the best decision possible.”
The Force add-on for ClaimCenter allows insurers to:
- Send claims from ClaimCenter to Force for real-time fraud analysis;
- Keep ClaimCenter up to date with the status of fraud investigations; and
- Customize the level of information provided to claims representatives.
“While speed and accuracy are critical elements to delivering an exceptional customer experience in the insurance industry, the prospect of fraud within the claims process often limits just how quickly a claim can be settled,” explains Becky Mattick, vice president, Global Solution Alliances, Guidewire. “With a fraud assessment available in seconds, through Shift’s Ready for Guidewire integration, Guidewire customers can make smarter, faster and more efficient decisions about how to triage claims, unlocking greater opportunities for straight-through processing, shortening the claims process, and delivering on policyholder expectations.”
Please find more information about Shift Technology on the Guidewire Smart Approach blog .
About Shift Technology
Shift Technology delivers the only AI-native fraud detection and claims automation solutions built specifically for the global insurance industry. Our SaaS solutions identify individual and network fraud with double the accuracy of competing offerings, and provide contextual guidance to help insurers achieve faster, more accurate claim resolutions. Shift has analyzed hundreds of millions of claims to date and was named by CB Insights to the 2018 Global AI Top 100. For more information please visit www.shift-technology.com .
About Guidewire PartnerConnect and Ready for Guidewire
Guidewire PartnerConnect is a global network of select companies that provide consulting services and solutions to enhance, extend, and complement the capabilities of Guidewire products. Our worldwide community helps contribute to the success of our mutual customers in the general insurance industry by delivering Guidewire software implementations, value-add solution and technology offerings, and guidance on insurance industry best practices.
Guidewire DevConnect is a developer platform that enables Guidewire PartnerConnect Solution partners to create innovative add-ons that integrate with Guidewire InsurancePlatform products. DevConnect add-ons feature straight forward installation, full-fidelity upgrades, and enhanced support - enabling insurers to focus on innovation and growth. With a complete set of APIs, software development kits, and associated tools, DevConnect provides everything that the independent general insurance developer community needs to rapidly design and build feature-rich add-ons for Guidewire products and publish them in the Guidewire Marketplace.
Guidewire PartnerConnect is an invitation-only program. For more information about Guidewire PartnerConnect please visit http://www.guidewire.com/partners/ .
About Guidewire Software
Guidewire delivers the industry platform that general insurers rely upon to adapt and succeed in a time of accelerating change. We provide the software, services, and partner ecosystem to enable our customers to run, differentiate, and grow their business. As of the end of our fiscal year 2019, we were privileged to serve more than 380 companies in 34 countries. For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200312005177/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom